A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13 (TM) in Healthy Infants [Estudio multicentrico y doble ciego de la seguridad, la tolerabilidad y la inmunogenicidad de una vacuna antineumococica conjugada (V114) en comparacion con Prevenar 13 (TM) en lactantes sanos]
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2012
At a glance
- Drugs Aluminium compounds; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal-15-valent-vaccine-conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- 15 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 31 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jul 2012 Pfizer added as associations as reported in the European Clinical Trials Database record.